On the onset, everything looks bad about this company except PRICE ACTION & FY23 AR (Especially Director's Report)
Some Key factors in the report
- Strategy of moving business to focussed subsidiaries has been successful - Asence Pharma has started a new Oncology and Synthetic API plant - Synbiotics is manufacturing an antifungal active ingredient - Amphotericin B - Sarabhai M Chemicals has started manufacturing Vitamin C coated products - Vovantis Labs has setup a state of art manufacturing facility to expand business - CoSara DIagnostics has the exclusive manufacturing rights in India for the complete menu of its US partner - Co-Diagnostics
So many turnaround factors which is clearly indicated by Price Action
Technicals
On a monthly chart, PA has formed a CUP and HANDLE with breakout. This is a powerful indication of confirming the fundamentals stated above.
This pick is for those who like turnaround candidates (dark horse)
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.